GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » Other Operating Expense

Melodiol Global Health (ASX:ME1DE) Other Operating Expense : A$12.96 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Other Operating Expense?

Melodiol Global Health's Other Operating Expense for the six months ended in Dec. 2023 was A$10.51 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$12.96 Mil.

Melodiol Global Health's quarterly Other Operating Expense declined from Dec. 2022 (A$7.17 Mil) to Jun. 2023 (A$2.45 Mil) but then increased from Jun. 2023 (A$2.45 Mil) to Dec. 2023 (A$10.51 Mil).

Melodiol Global Health's annual Other Operating Expense declined from Dec. 2021 (A$17.76 Mil) to Dec. 2022 (A$11.58 Mil) but then increased from Dec. 2022 (A$11.58 Mil) to Dec. 2023 (A$12.96 Mil).


Melodiol Global Health Other Operating Expense Historical Data

The historical data trend for Melodiol Global Health's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Other Operating Expense Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial 5.68 5.90 17.76 11.58 12.96

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.93 4.41 7.17 2.45 10.51

Melodiol Global Health Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$12.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (ASX:ME1DE) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines